Emcure Pharmaceuticals Q1 Profit Jumps 42% on Strong Revenue and Margin Growth

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628

reported a robust performance for the first quarter of FY27, with consolidated net profit rising 42% year-on-year to ₹294 crore from ₹207 crore in the corresponding quarter last year. Revenue from operations increased 22.8% to ₹2,580 crore, driven by healthy growth across its domestic and international pharmaceutical businesses. The company's operating performance also strengthened during the quarter. EBITDA grew 27.8% year-on-year to ₹533 crore from ₹417 crore, while the EBITDA margin expanded by 90 basis points to 20.7% from 19.8% a year ago, reflecting improved operational efficiency and a favourable product mix. The board also appointed Satish Mehta, the company's CEO and founder, as Chairman. Industry & Economic Impact: The results highlight the continued strength of India's pharmaceutical sector, supported by growing demand for branded formulations, specialty medicines, and exports. Higher revenue and margin expansion indicate improving operational efficiency and sustained demand across key therapeutic segments. From an economic perspective, sustained growth in pharmaceutical manufacturing supports exports, research and development, skilled employment, and healthcare innovation. Continued expansion by companies like Emcure Pharmaceuticals strengthens India's position as a global pharmaceutical manufacturing hub and contributes to long-term industrial and economic growth. Source: NDTV Profit No Recommendations